<SEC-DOCUMENT>0000950170-24-078462.txt : 20240627
<SEC-HEADER>0000950170-24-078462.hdr.sgml : 20240627
<ACCEPTANCE-DATETIME>20240627161503
ACCESSION NUMBER:		0000950170-24-078462
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20240625
FILED AS OF DATE:		20240627
DATE AS OF CHANGE:		20240627

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Hughes-Wilson Alexandra
		CENTRAL INDEX KEY:			0002005875
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38452
		FILM NUMBER:		241079440

	MAIL ADDRESS:	
		STREET 1:		C/O MEREO BIOPHARMA
		STREET 2:		1 CAVENDISH PLACE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1G 0QF

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Mereo BioPharma Group plc
		CENTRAL INDEX KEY:			0001719714
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		ONE CAVENDISH PLACE
		STREET 2:		FOURTH FLOOR
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1G0QF
		BUSINESS PHONE:		4403330237300

	MAIL ADDRESS:	
		STREET 1:		ONE CAVENDISH PLACE
		STREET 2:		FOURTH FLOOR
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1G0QF

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Mereo Biopharma Group plc
		DATE OF NAME CHANGE:	20171016
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2024-06-25</periodOfReport>

    <issuer>
        <issuerCik>0001719714</issuerCik>
        <issuerName>Mereo BioPharma Group plc</issuerName>
        <issuerTradingSymbol>MREO</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0002005875</rptOwnerCik>
            <rptOwnerName>Hughes-Wilson Alexandra</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O MEREO BIOPHARMA GROUP PLC</rptOwnerStreet1>
            <rptOwnerStreet2>4TH FLOOR, ONE CAVENDISH PLACE</rptOwnerStreet2>
            <rptOwnerCity>LONDON</rptOwnerCity>
            <rptOwnerState>X0</rptOwnerState>
            <rptOwnerZipCode>W1G 0QF</rptOwnerZipCode>
            <rptOwnerStateDescription>UNITED KINGDOM</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>false</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>See Remarks</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>American Depositary Shares representing Ordinary Shares</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <transactionDate>
                <value>2024-06-25</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>10134</value>
                    <footnoteId id="F2"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>3.6939</value>
                    <footnoteId id="F3"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>57516</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>American Depositary Shares representing Ordinary Shares</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <transactionDate>
                <value>2024-06-26</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>22968</value>
                    <footnoteId id="F2"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>3.3932</value>
                    <footnoteId id="F4"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>34548</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Each American Depositary Share (&quot;ADS&quot;) represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.</footnote>
        <footnote id="F2">Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the &quot;Plan&quot;), that vested on June 21, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a &quot;sell to cover&quot; transaction and do not represent discretionary trades by the Reporting Person.</footnote>
        <footnote id="F3">The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.60 to $3.805, inclusive. The Reporting
Person undertakes to provide to Mereo BioPharma Group plc (&quot;Mereo&quot;), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.</footnote>
        <footnote id="F4">The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.28 to $3.51, inclusive.</footnote>
    </footnotes>

    <remarks>Chief Patient Access and Commercial Planning</remarks>

    <ownerSignature>
        <signatureName>/s/ Christine Fox, by power of attorney</signatureName>
        <signatureDate>2024-06-27</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
